Navigation Links
Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff

LAWRENCEVILLE, Ga. and CARDIFF, Wales, Sept. 21, 2011 /PRNewswire/ -- Genesis Biosciences, a global leader in custom fermentation, microbial product formulation and antimicrobial product development, announced today that Casey Smallwood has been promoted to vice president of operations. Additionally, Mauricio Amaya and Amit Choksi have been promoted to laboratory manager and fermentation manager, respectively, and Prasanth Maddipati joins Genesis as a new fermentation scientist. These team members will be located in Genesis' newly renovated U.S. fermentation and manufacturing facility in Lawrenceville, GA.


"Casey, Mauricio, Amit and Prasanth bring valuable experience and knowledge to the Genesis operational and technical teams, and we will look to them as we continue to develop high-quality, environmentally preferred chemical, fermentation and microbial-based solutions for our customers," stated Conrad Mielcuszny, president and chief executive officer of Genesis Biosciences.

Casey Smallwood, Vice President of Operations

Casey Smallwood brings to Genesis more than 20 years of chemical development and production management  experience in the household and institutional as well as janitorial and sanitation arenas. In his role as vice president of operations, Smallwood will oversee all manufacturing and production, customer service, telesales and equipment engineering/maintenance at Genesis. Smallwood joined Genesis Biosciences (formerly Genesis Technologies) in 2000, and he has held the positions of operations manager, production manager and customer service manager. Prior to joining Genesis, Smallwood served as operations manager at Harvard Chemical Research, a chemical manufacturer of institutional and household compounds specializing in carpet care and the primary chemical manufacturer for professional carpet systems franchises. Smallwood attended Clayton State University.

Mauricio Amaya, Laboratory Manager

Mauricio Amaya has more than 17 years of experience in formulation, research and development and regulatory experience in the microbial and specialty chemicals industries. As laboratory manager, Amaya will oversee all aspects of the Genesis' laboratory, including overall microbiological quality control for production and fermentation, chemical quality control, research and product development and customer technical support. Amaya was previously chief chemist at Genesis. Prior to joining the company, Amaya was the director of technical services at Atco International where he managed the Technical Department, which included duties such as quality control, product research and development and regulatory affairs. Amaya received a B.S. in chemistry from Oglethorpe University and an M.S. in technology management from Mercer University.

Amit Choksi, Fermentation Manager

Amit Choksi brings a breadth of laboratory and bacteria fermentation training and experience to Genesis. As fermentation manager, Choksi oversees a team of scientist and operators that manage the research, design, planning and execution of laboratory and large-scale fermentation studies of bacteria in adherence with Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Prior to joining Genesis, Choksi was a fermentation microbiologist at Merial Limited, a research-based veterinary pharmaceutical division of Merck. In this role, he designed planned and carried out laboratory studies in bacteria, developed upstream fermentation methods using bench scale and pilot scale fermentors and helped develop a new canine vaccine. Prior to that, Choksi was a scientist at Fort Dodge Animal Health, a research-based veterinary pharmaceutical division of Wyeth Pharmaceuticals, and a laboratory technician at Severn Trent Laboratory. Choksi received a B.S. in biology from The Ohio State University.

Prasanth Maddipati, Fermentation Scientist

Prasanth Maddipati joins Genesis with a solid background in bioprocess engineering, including the design and execution of microbial fermentation processes. At Genesis, he plays an important role in the monitoring and optimization of the company's fermentors and fermentation operations to help ensure accuracy and quality control. Prior to joining Genesis, Maddipati was a graduate research assistant at Oklahoma State University where he worked on fermentation of syngas to ethanol and other value-added products using a novel microbial catalyst. Maddipati has authored several publications in Bioresource Technology and has served as a panel speaker at leading biotechnology and bioengineering conferences. Maddipati received a B.Tech in industrial biotechnology from Anna University in India and an M.S. in biosystems engineering from Oklahoma State University.

Genesis Biosciences was formed in 2009 when United Kingdom-based Biotal Technologies and Lawrenceville, Georgia-based Genesis Technologies were first acquired and then merged by the CKM Group. Genesis Biosciences is a market leader in bacteria fermentation and is the first company to develop, manufacture and offer both microbial and antimicrobial products. Based on the knowledge and experience of the company's scientists and lab technicians, the company utilizes its in-house fermentation equipment and facilities to grow bacteria to the highest quality known in the marketplace. Additionally, Genesis creates solutions for the safe and natural eradication of bacteria using plant oils, essential oils and green chemistry.

About Genesis Biosciences

Genesis Biosciences is a biotechnology company specializing in bacteria fermentation, microbial, antimicrobial and environmentally preferred products and services. The company focuses its efforts on the development of diverse quality-assured products and solutions for a wide range of markets and applications. Genesis Biosciences emphasizes quality in every aspect of its business to ensure the most efficient solutions to meet customers' needs. Genesis Biosciences' U.S. facility is located in Lawrenceville, Georgia, and its European facility is in Cardiff, Wales. For more information, please visit  

SOURCE Genesis Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ALBANY, New York , November 24, 2015 /PRNewswire/ ... According to a recent market research report released by ... is projected to expand at a CAGR of 17.5% ... titled "Non-invasive Prenatal Testing Market - Global Industry Analysis, ... 2022", estimates the global non-invasive prenatal testing market to ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):